Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The CANYON study is a multicenter, randomized, Phase 2, double-blind, placebo-controlled
study to evaluate the effect of EDG-5506 on the safety, pharmacokinetics (PK), biomarkers,
and functional measures in adults and adolescents with Becker Muscular Dystrophy (BMD).